Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P

Phase 3 Completed 83 enrolled Kirby Institute AbbVie · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

An open label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin or glecaprevir/pibrentasvir for people with recently acquired hepatitis C virus infection with or without HIV co-infection.

Timeline

Start: 2016-06
Primary completion: 2021-04-30
Completion: 2021-04-30

Publications

Martinello M, Bhagani S, Shaw D, Orkin C, Cooke G, Gane E, Iser D, Ustianowski A, Kulasegaram R, Stedman C, Tu E, Grebely J, Dore GJ, Nelson M, Matthews GV. Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study. JHEP Rep. 2023 Jul 27;5(10):100867. doi: 10.1016/j.jhepr.2023.100867. eCollection 2023 Oct.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ribavirin	Small molecule	1000 mg	Oral
Subject	Ribavirin	Small molecule	1200 mg	Oral
Subject	Ritonavir	Other / unclassified	50 mg	Oral
Subject	dasabuvir	Small molecule	250 mg	Oral
Subject	glecaprevir	Other / unclassified	100 mg	Oral
Subject	ombitasvir	Small molecule	12.5 mg	Oral
Subject	paritaprevir	Small molecule	75 mg	Oral
Subject	pibrentasvir	Other / unclassified	40 mg	Oral

Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P

Summary

Timeline

Publications

Drugs

Indications